Benitec Biopharma Inc. (BNTC): Insider Trading, Congress Trades & Research | Tormere

BNTC

$9.28+10.48%visit website

Benitec Biopharma Inc.

Market Cap

$324M

Live price × SEC shares (Sep 4, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.27

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

1.8

Mkt cap / shareholders' equity

Flagged input, hover for details

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q1 FY2026 Sep 30, 2025	Q2 FY2026 Dec 31, 2025	Q3 FY2026 Mar 31, 2026	Q4 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	0.00	0.00	0.00
Research & development	3,370	5,834	6,298	7,886	23,388
Total operating expenses	9,803	13,377	13,582	14,430	51,192
Operating income	(9,803)	(13,377)	(13,582)	(14,430)	(51,192)
Income tax					0.00
Net income	(8,965)	(11,837)	(11,935)	(12,809)	(45,546)
EPS (basic) ($)	(0.22)	(0.26)	(0.24)		(0.98)
EPS (diluted) ($)	(0.22)	(0.26)	(0.24)		(0.98)
Weighted avg. shares (basic)	41,521	45,971	49,386
Weighted avg. shares (diluted)	41,521	45,971	49,386

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-K filed Sep 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 24 more quarters, back to Sep 2019, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

Yahoo · 2026-10-28

Every patient in Benitec’s study responded to an experimental treatment for a disease that weakens swallowing.

Stock Titan · 2026-10-28

Benitec Biopharma Announces Its Interim Data From BB-301 Phase 1b/2a Trial Shows Continued Durable Enhancements In Participants Treated With Low Dose Of BB-301; 100% Response Rate Seen Across All Patients Treated

Benzinga · 2026-10-28

(BNTC) Risk Channels and Responsive Allocation

Stock Traders Daily · 2026-10-26

This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Benzinga · 2026-10-23

Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14

Benzinga · 2026-10-23

Enterprise value to EBIT forward of Benitec Biopharma Inc. – NASDAQ:BNTC

TradingView · 2026-10-11

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

Yahoo Finance · 2026-10-05

After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)

Yahoo Finance · 2026-09-25

BENITEC BIOPHARMA Q4 2026 Earnings Preview: Recent $BNTC Insider Trading, Hedge Fund Activity, and More

Quiver Quantitative · 2026-09-19

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

Yahoo Finance · 2026-09-14

Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation

Simply Wall St · 2026-08-07

BNTC Forecast — Price Target — Prediction for 2027

TradingView · 2026-06-25

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

Yahoo Finance · 2026-05-14

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Yahoo Finance · 2026-04-28

Informational purposes only, not investment advice.